Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14(ARF) Tumor Suppressor Genes

The adenovirus mutant ONYX-015 is in phase III clinical trials as a novel antitumor therapy. Its apparent efficacy is thought to be due to its ability to replicate selectively in tumor cells defective in the signaling pathway for p53. Recent data have shown that p14(ARF), a positive regulator of p53...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Edwards, Sara J., Dix, Brett R., Myers, Colleen J., Dobson-Le, Deirdre, Huschtscha, Lily, Hibma, Merilyn, Royds, Janice, Braithwaite, Antony W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2002
Assuntos:
Replication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC136704/
https://ncbi.nlm.nih.gov/pubmed/12438574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.76.24.12483-12490.2002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados